Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice

International Journal of Developmental Neuroscience

Volumn 24, Issue 2-3, 2006, Pages 195-201

  Siegemund, T ^a   Paulke, B R ^b   Schmiedel, H ^a   Bordag, N ^a   Hoffmann, A ^a   Harkany, T ^c   Tanila, H ^d   Kacza, J ^a   Hartig W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b FRAUNHOFER INSTITUTE FOR APPLIED POLYMER RESEARCH   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Alzheimer's disease; Drug delivery; Drug targeting; Dynamic light scattering; Senile plaque

Indexed keywords

AMYLOID BETA PROTEIN; CYANOACRYLATE; DRUG CARRIER; ESTERASE; POLYMER; POLYSTYRENE; THIOFLAVINE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIODEGRADATION; BRAIN CORTEX; COLLOID; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BINDING; DRUG TARGETING; ENZYMATIC DEGRADATION; HIPPOCAMPUS; IN VITRO STUDY; LIGHT SCATTERING; LIVER; MOUSE; NANOPARTICLE; NONHUMAN; PRIORITY JOURNAL; SPECTROFLUOROMETRY; SWINE; TRANSGENIC ORGANISM;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NANOSTRUCTURES; NEUROFIBRILLARY TANGLES; PROTEIN BINDING; THIAZOLES; TIME FACTORS;

ANIMALIA; MUS MUSCULUS; SUIDAE; SUS SCROFA;

EID: 33644553876     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2005.11.012     Document Type: Conference Paper

References (58)

1. C. Adessi, M.-J. Frossard, C. Boissard, S. Fraga, S. Bieler, T. Ruckle, F. Vilbois, S.M. Robinson, M. Mutter, W.A. Banks, and C. Soto Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease J. Biol. Chem. 278 2003 13905 13911
2. J. Apelt, and R. Schliebs β-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology Brain Res. 894 2001 21 30
3. B.J. Bacskai, G.A. Hickey, J. Skoch, S.T. Kajdasz, Y. Wang, G.-f. Huang, C.A. Mathis, W.E. Klunk, and B.T. Hyman Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice Proc. Natl. Acad. Sci. U.S.A. 100 2003 12462 12467
4. P. Ballabh, A. Braun, and M. Nedergaard The blood-brain barrier: an overview. Structure, regulation, and clinical implications Neurobiol. Dis. 16 2004 1 13
5. D.J. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol. Therapeut. 104 2004 29 45
6. D.R. Borchelt, T. Ratovitski, J. van Lare, M.K. Lee, V. Gonzales, N.A. Jenkins, N.G. Copeland, D.L. Price, and S.S. Sisodia Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins Neuron 19 1997 939 945
7. P. Calvo, B. Gouritin, H. Chacun, D. Desmaele, J. D'Angelo, J.P. Noel, D. Georgin, E. Fattal, J.P. Andreux, and P. Couvreur Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery Pharm. Res. 18 2001 1157 1166
8. K.A. Conway, E.W. Baxter, K.M. Felsenstein, and A.B. Reitz Emerging beta-amyloid therapies for the treatment of Alzheimer's disease Curr. Pharm. Des. 9 2003 427 447
9. K.N. Dahlgren, A.M. Manelli, W.B. Stine Jr., L.K. Baker, G.A. Krafft, and M.J. LaDu Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability J. Biol. Chem. 277 2002 32046 32053
10. G.V. De Ferrari, W.D. Mallender, N.C. Inestrosa, and T.L. Rosenberry Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites J. Biol. Chem. 276 2001 23282 23287
11. J.-C. Dodart, K.R. Bales, and S.M. Paul Immunotherapy for Alzheimer's disease: will vaccination work? Trends Mol. Med. 9 2003 85 87
12. K. Duff, and M.V. Rao Progress in the modeling of neurodegenerative diseases in transgenic mice Curr. Opin. Neurol. 14 2001 441 447
13. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
14. J.B. Fishman, J.B. Rubin, J.V. Handrahan, J.C. Connor, and R.E. Fine Receptor-mediated transcytosis of transferrin across the blood-brain barrier J. Neurosci. Res. 18 1987 299 304
15. A. Gessner, A. Lieske, B.-R. Paulke, and R.H. Müller Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis Eur. J. Pharm. Biopharm. 54 2002 165 170
16. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere, and P. Speiser Pharmacokinetics and distribution of a biodegradable drug carrier Int. J. Pharm. 15 1983 335 345
17. A. Gulati, C. Nath, K. Shanker, R.C. Srimal, K.N. Dhawan, and K.P. Bhargava Effect of alkohols on the permeability of blood-brain barrier Pharmacol. Res. Commun. 17 1985 85 92
18. A.E. Gulyaev, S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, and J. Kreuter Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles Pharm. Res. 16 1999 1564 1569
19. T. Harkany, I. Abraham, C. Konya, C. Nyakas, M. Zarandi, B. Penke, and P.G. Luiten Mechanisms of beta amyloid neurotoxicity: perspectives of pharmacotherapy Rev. Neurosci. 11 2000 329 382
20. W. Härtig, B.-R. Paulke, C. Varga, J. Seeger, T. Harkany, and J. Kacza Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease Neurosci. Lett. 338 2003 174 176
21. Härtig W., Paulke B.-R., Grosche J., Seeger J., Schmiedel H., Siegemund T., Harkany T., Tanila H., Kacza J., 2004. Targeting of β-Amyloid Deposits with Thioflavins Delivered from Nanoparticles in Transgenic Mice. Program No. 124.8, 2004 Abstract Viewer/Iterinary Planner. Society for Neuroscience, Washington, DC.
22. J.L. Jankowsky, D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, S.G. Younkin, and D.R. Borchelt Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase Hum. Mol. Genet. 13 2004 159 170
23. W.I. Klein, G.A. Krafft, and C.E. Finch Targeting small Aβ oligomers: the solution to an Alzheimer's disease conondrum? Trends Neurosci. 24 2001 219 224
24. W.E. Klunk, Y. Wang, G. Huang, M.L. Debnath, D.P. Holt, and C.A. Mathis Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci. 69 2001 1471 1484
25. J. Kreuter, V.E. Petrov, D.A. Kharkevich, and R.N. Alyautdin Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles J. Control. Release 49 1997 81 87
26. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 2001 65 81
27. J. Kreuter Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain J. Nanosci. Nanotech. 4 2004 484 488
28. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 2002 317 325
29. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D.J. Begley Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 2003 409 416
30. F.M. LaFerla, and S. Oddo Alzheimer's disease: Aβ, tau and synaptic dysfunction Trends Mol. Med. 11 2005 170 176
31. D.L. LaVan, T. McGuire, and R. Langer Small-scale systems for in vivo drug delivery Nat. Biotechnol. 21 2003 1184 1191
32. P.R. Lockman, J.M. Koziara, R.J. Mumper, and D.D. Allen Nanoparticle surface charges alter blood-brain barrier integrity and permeability J. Drug Target. 12 2004 635 641
33. P.P. Mager, B. Penke, R. Walter, T. Harkany, and W. Härtig Pathological peptide folding in Alzheimer's disease and other conformational disorders Curr. Med. Chem. 9 2002 1763 1780
34. C.A. Mathis, Y. Wang, and W.E. Klunk Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain Curr. Pharm. Des. 10 2004 1469 1492
35. A. Misra, S. Ganesh, and A. Shahiwala Drug delivery to the central nervous system: a review J. Pharm. Pharmaceut. Sci. 6 2003 252 273
36. T. Mueggler, M. Meyer-Luehmann, M. Rausch, M. Staufenbiel, M. Jucker, and M. Rudin Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis Eur. J. Neurosci. 20 2004 811 817
37. R.H. Müller, C. Lherm, J. Herbort, and P. Couvreur In vitro model for the degradation of alkylcyanoacrylate nanoparticles Biomaterials 11 1990 590 595
38. W.M. Pardridge Brain Drug Targeting 2001 Cambridge University Press Cambridge
39. B.-R. Paulke, P.-M. Möglich, E. Knippel, A. Budde, R. Nitzsche, and R.H. Müller Electrophoretic 3D-mobility profiles of latex particles with different surface groups Langmuir 11 1995 70 74
40. B. Permanne, C. Adessi, G.P. Saborio, S. Fraga, M.-J. Frossard, J. Van Dorpe, I. Dewachter, W.A. Banks, F. Van Leuven, and C. Soto Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide FASEB J. 16 2002 860 867
41. I. Sauer, I.R. Dunay, K. Weisgraber, M. Bienert, and M. Dathe An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells Biochemistry 44 2005 2021 2029
42. A. Savonenko, G.M. Xu, T. Melnikova, J.L. Morton, V. Gonzales, M.P. Wong, D.L. Price, F. Tang, A.L. Markowska, and D.R. Borchelt Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities Neurobiol. Dis. 18 2005 602 617
43. S.A. Schnell, W.A. Staines, and M.W. Wessendorf Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue J. Histochem. Cytochem. 47 1999 719 730
44. U. Schroeder, P. Sommerfeld, S. Ulrich, and B.A. Sabel Nanoparticle technology for delivery of drugs across the blood-brain barrier J. Pharm. Sci. 87 1998 1305 1307
45. D.J. Selkoe Alzheimer's disease: genes, proteins and therapy Phys. Rev. 81 2001 741 766
46. D.M. Skovronsky, B. Zhang, M.-P. Kung, H.F. Kung, J.Q. Trojanowski, and V.M.-Y. Lee In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 97 2000 7609 7614
47. P. Sommerfeld, B.A. Sabel, and U. Schroeder Long-term stability of PBCA nanoparticle suspensions J. Microencapsul. 17 2000 69 79
48. S.C.J. Steiniger, J. Kreuter, A.S. Khalansky, I.N. Skidan, A.I. Bobruskin, Z.S. Smirnova, S.E. Severin, R. Uhl, M. Kock, K.D. Geiger, and S.E. Gelperina Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int. J. Cancer 109 2004 759 767
49. E.A. Stern, B.J. Bacskai, G.A. Hickey, F.J. Attenello, J.A. Lombardo, and B.T. Hyman Cortical synaptic integraty in vivo is disrupted by amyloid-β plaques J. Neurosci. 24 2004 4535 4540
50. C.O. Sullivan, and C. Birkinshaw In vitro degradation of insulin-loaded poly(n-butylcyanoacrylate) nanoparticles Biomaterials 25 2004 4375 4382
51. J. Tsai, J. Grutzendler, K. Duff, and W.B. Gan Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches Nat. Neurosci. 7 2004 1181 1183
52. A. Tsuji, and I. Tamai Carrier-mediated or specialized transport of drugs across the blood-brain barrier Adv. Drug Deliv. Rev. 36 1999 277 290
53. P.L. Tuma, and A.L. Hubbard Transcytosis: crossing cellular barriers Physiol. Rev. 83 2003 871 932
54. E.S. Voropai, M.P. Samtsov, K.N. Kaplevskii, A.A. Maskevich, V.I. Stepuro, O.I. Povarova, I.M. Kuznetsova, K.K. Turoverov, A.L. Fink, and V.N. Uverskii Spectral properties of thioflavin T and its complexes with amyloid fibrils J. Appl. Spectrosc. 70 2003 868 874
55. J. Wang, H. Tanila, J. Puoliväli, I. Kadish, and T. van Groen Gender differences in the amount and deposition of amyloid β in APPswe and PS1 double transgenic mice Neurobiol. Dis. 14 2003 318 327
56. K.J. Whittlesey, and L.D. Shea Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface Exp. Neurol. 190 2004 1 16
57. H. Wolburg, K. Wolburg-Buchholz, and B. Engelhardt Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact Acta Neuropathol. 109 2005 181 190
58. Z.-P. Zhuang, M.-P. Kung, C. Hou, D.M. Skovronsky, T.L. Gur, K. Plössl, J.Q. Trojanowski, and H.F. Kung Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates J. Med. Chem. 44 2001 1905 1914